Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARQT Arcutis Biotherapeutics Inc.

盘前交易 07-30 08:56:58 EDT

27.86

-0.56

-1.97%

盘前28.38

+0.52+1.87%

04:00 EDT

最高28.53	最低27.72	成交量97.73万
今开28.18	昨收28.42	日振幅2.83%
总市值34.85亿	流通市值25.79亿	总股本1.25亿
成交额2,738万	换手率1.06%	流通股本9,257万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":27.86,"timestamp":1785355200000,"preClose":28.42,"halted":0,"volume":977252,"hourTrading":{"tag":"盘前","latestPrice":28.38,"preClose":27.86,"latestTime":"04:00 EDT","volume":2,"amount":56.76,"timestamp":1785398417725,"change":0.52,"changeRate":0.018665,"amplitude":0},"delay":0,"changeRate":-0.019704433497537026,"floatShares":92571299,"shares":125073249,"eps":-0.02,"marketStatus":"盘前交易","change":-0.56,"latestTime":"07-30 08:56:58 EDT","open":28.18,"high":28.525,"low":27.72,"amount":27375750.50348,"amplitude":0.028325,"askPrice":30,"askSize":6,"bidPrice":27.77,"bidSize":66,"shortable":3,"etf":0,"ttmEps":-0.02,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785418200000},"marketStatusCode":1,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":27.86,"preHourTrading":{"tag":"盘前","latestPrice":28.38,"preClose":27.86,"latestTime":"04:00 EDT","volume":2,"amount":56.76,"timestamp":1785398417725,"change":0.52,"changeRate":0.018665,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":27.8954,"preClose":27.86,"latestTime":"19:34 EDT","volume":19226,"amount":535613.7708,"timestamp":1785368047361,"change":0.0354,"changeRate":0.001271,"amplitude":0.00163},"volumeRatio":0.9934728282156697,"impliedVol":0.4995,"impliedVolPercentile":0.244},"requestUrl":"/m/hq/s/ARQT","defaultTab":"news","newsList":[{"id":"1101101203","title":"FDA受理Arcutis旗下Zoryve®（罗氟司特）乳膏0.05%补充新药申请，用于治疗低至3月龄婴儿的轻中度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1101101203","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101101203?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512078,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理Arcutis Biotherapeutics Inc. (ARQT) 旗下产品Zoryve®（罗氟司特）乳膏0.05%的补充新药申请。该申请旨在扩展该药物的适应症，用于治疗年龄低至3个月婴儿的轻中度特应性皮炎。这一进展标志着该疗法在满足年幼患者群体未竟医疗需求的道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167416883","title":"Arcutis Biotherapeutics：FDA为Zoryve乳膏0.05% sNDA设定2027年2月23日PDUFA目标行动日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1167416883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167416883?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512075,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics公司宣布，美国食品药品监督管理局已为其Zoryve乳膏0.05%的补充新药申请设定了处方药使用者付费法案目标行动日期，定于2027年2月23日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193550139","title":"FDA批准Arcutis旗下Zoryve®（罗氟司特）乳膏0.3%用于治疗低至2岁儿童的斑块状银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1193550139","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193550139?lang=zh_cn&edition=full","pubTime":"2026-06-30 07:07","pubTimestamp":1782774434,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准Arcutis Biotherapeutics Inc.旗下产品Zoryve®（罗氟司特）乳膏0.3%用于治疗斑块状银屑病，其适用患者年龄范围扩展至最低两岁的儿童。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180888150","title":"Arcutis Biotherapeutics依据纳斯达克上市规则5635(C)(4)报告激励性股权授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1180888150","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180888150?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:19","pubTimestamp":1778271584,"startTime":"0","endTime":"0","summary":"生物制药公司Arcutis Biotherapeutics Inc.宣布，其已根据纳斯达克股票市场的上市规则5635(C)(4)条款，完成了新一轮激励性股权授予。该规则主要适用于新入职员工，允许公司在不经过股东批准的情况下授予股权激励，旨在吸引和留住关键人才。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131553441","title":"Arcutis向FDA提交Zoryve®乳膏补充新药申请 拟将特应性皮炎适应症扩展至3个月大婴儿","url":"https://stock-news.laohu8.com/highlight/detail?id=1131553441","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131553441?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:05","pubTimestamp":1777291534,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. (ARQT) 已向美国食品药品监督管理局（FDA）提交了一份补充新药申请（sNDA），旨在将其产品Zoryve®（罗氟司特）0.05%乳膏的适应症范围扩大，用于治疗低至3个月婴儿的特应性皮炎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175483042","title":"Arcutis旗下Zoryve®（罗氟司特）乳膏获美国皮肤病学会首个儿童特应性皮炎指南强力推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1175483042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175483042?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:03","pubTimestamp":1776859424,"startTime":"0","endTime":"0","summary":"在最新发布的美国皮肤病学会（AAD）首部儿童特应性皮炎临床指南中，Arcutis Biotherapeutics Inc. (ARQT) 旗下的Zoryve®（罗氟司特）乳膏获得了强烈推荐。这一历史性指南的认可，标志着该疗法在儿科皮肤病治疗领域的重要地位得到确立。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197315235","title":"Arcutis公布Zoryve®（罗氟司特）乳膏0.05%治疗2至5岁儿童轻中度特应性皮炎长期积极安全性和有效性数据发表于《儿科皮肤病学》","url":"https://stock-news.laohu8.com/highlight/detail?id=1197315235","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197315235?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:06","pubTimestamp":1773147980,"startTime":"0","endTime":"0","summary":"生物制药公司Arcutis Biotherapeutics Inc.宣布，其Zoryve®（罗氟司特）乳膏0.05%用于治疗2至5岁儿童轻中度特应性皮炎的长期积极安全性和有效性数据，已在权威医学期刊《儿科皮肤病学》上正式发表。\n该研究数据证实，Zoryve®乳膏在此低龄患者群体中展现出持久的疗效和良好的耐受性，为儿科特应性皮炎的治疗提供了新的重要循证依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197207844","title":"Arcutis启动Arq-234一期1a/1b研究入组，评估CD200R激动剂在健康志愿者及特应性皮炎成人患者中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1197207844","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197207844?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:06","pubTimestamp":1772543187,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. (ARQT) 已正式启动其候选药物Arq-234的一期1a/1b临床研究，并开始招募受试者。该项研究旨在评估这款CD200R激动剂在健康志愿者以及患有特应性皮炎的成人群体中的安全性与耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355756","title":"Arcutis Biotherapeutics, Inc.2025财年实现净利润-16.14百万美元，同比增加88.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355756?lang=zh_cn&edition=full","pubTime":"2026-03-02 00:00","pubTimestamp":1772380845,"startTime":"0","endTime":"0","summary":"3月2日，Arcutis Biotherapeutics, Inc.公布财报，公告显示公司2025财年净利润为-16.14百万美元，同比增加88.47%；其中营业收入为3.76亿美元，同比增加90.86%，每股基本收益为-0.13美元。从资产负债表来看，Arcutis Biotherapeutics, Inc.总负债2.43亿美元，其中短期债务1000000.00美元，资产负债比为1.79，流动比率为3.17。机构评级：截至2026年3月2日，当前有8家机构对Arcutis Biotherapeutics, Inc.目标价做出预测，其中目标均价为34.75美元，其中最低目标价为33.00美元，最高目标价为36.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302000054a43e8c0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302000054a43e8c0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158440689","title":"财报前瞻｜Arcutis Biotherapeutics Inc.本季度营收预计增87.93%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1158440689","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158440689?lang=zh_cn&edition=full","pubTime":"2026-02-18 12:20","pubTimestamp":1771388407,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc.将于2026年2月25日发布最新季度财报，市场关注收入高增与费用结构变化对盈利弹性的综合影响。市场一致预期Arcutis Biotherapeutics Inc.本季度营收约为1.13亿USD，同比增长87.93%；调整后每股收益预计为0.10USD，同比增长139.77%，当前未见针对毛利率与净利率的量化一致预期，亦未见明确的净利润预测。上季度公司实现营收9,921.90万USD，同比增长121.69%；毛利率为91.25%；归属于母公司股东的净利润为741.00万USD，净利率为7.47%；调整后每股收益为0.06USD，同比增长118.18%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Arcutis Biotherapeutics Inc.本季度营收预计增87.93%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121503985","title":"Arcutis Biotherapeutics依据纳斯达克规则5635(c)(4)授予新员工股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=1121503985","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121503985?lang=zh_cn&edition=full","pubTime":"2026-02-06 05:06","pubTimestamp":1770325617,"startTime":"0","endTime":"0","summary":"加州西湖村，2026年2月5日——专注于免疫皮肤病学领域创新疗法研发的商业化阶段生物制药公司Arcutis Biotherapeutics Inc.今日宣布，依据纳斯达克上市规则5635，向12名新入职员工授予总计94,000股公司普通股的限制性股票单位。该奖励已由Arcutis董事会薪酬委员会批准，根据Arcutis Biotherapeutics, Inc. 2022年诱导计划授予，授予日期为2026年2月2日，作为吸引新员工加入公司的重要激励措施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113476567","title":"Arcutis公布Zoryve®（罗氟司特）乳膏0.05%用于婴幼儿轻中度特应性皮炎的Integument-Infant二期试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1113476567","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113476567?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:04","pubTimestamp":1770037468,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. (ARQT) 宣布，其针对婴幼儿轻中度特应性皮炎（AD）的Zoryve®（罗氟司特）乳膏0.05%所进行的Integument-Infant二期临床试验，已获得积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517524988","title":"Arcutis Biotherapeutics, Inc.盘中异动 下午盘急速拉升5.22%报13.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517524988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517524988?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:56","pubTimestamp":1741114573,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日02时56分，Arcutis Biotherapeutics, Inc.股票出现波动，股价快速上涨5.22%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1293.93%、1186.20%、1169.09%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Celularity Inc C/Wts 16/07/2026 ，振幅分别为122.48%、68.89%、66.02%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030502561396398385&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030502561396398385&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630861","title":"Arcutis Biotherapeutics, Inc.盘中异动 大幅下跌5.04%报13.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630861?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:08","pubTimestamp":1741014524,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时08分，Arcutis Biotherapeutics, Inc.股票出现波动，股价大幅下挫5.04%。截至发稿，该股报13.00美元/股，成交量42.1476万股，换手率0.36%，振幅6.28%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1220.90%、127.04%、104.27%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、48.34%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230844989a1a89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230844989a1a89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516312557","title":"Arcutis Biotherapeutics, Inc.2024财年实现净利润-1.40亿美元，同比增加46.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516312557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516312557?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844864,"startTime":"0","endTime":"0","summary":"3月2日，Arcutis Biotherapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.40亿美元，同比增加46.56%；其中营业收入为1.97亿美元，同比增加230.48%，每股基本收益为-1.16美元。从资产负债表来看，Arcutis Biotherapeutics, Inc.总负债1.91亿美元，其中短期债务820000.00美元，资产负债比为1.83，流动比率为0.05。机构评级：截至2025年3月2日，当前有7家机构对Arcutis Biotherapeutics, Inc.目标价做出预测，其中目标均价为20.00美元，其中最低目标价为15.00美元，最高目标价为29.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000132abe2c5b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000132abe2c5b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516301367","title":"Arcutis Biotherapeutics, Inc.盘中异动 股价大涨5.08%报13.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301367","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516301367?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:46","pubTimestamp":1740775606,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时46分，Arcutis Biotherapeutics, Inc.股票出现异动，股价快速拉升5.08%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Camp4 Therapeutics Corporation、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3285.97%、607.09%、401.71%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.90%、48.19%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010446469896c6aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010446469896c6aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514333380","title":"高盛：维持Arcutis Biotherapeutics(ARQT.US)评级，由中性调整至中性评级, 目标价由13.00美元调整至15.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333380","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514333380?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:41","pubTimestamp":1740674501,"startTime":"0","endTime":"0","summary":"高盛：维持Arcutis Biotherapeutics(ARQT.US)评级，由中性调整至中性评级, 目标价由13.00美元调整至15.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28004148440835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857342","title":"瑞穗银行：维持Arcutis Biotherapeutics(ARQT.US)评级，由优于大市调整至优于大市评级, 目标价由20.00美元调整至21.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857342","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514857342?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Arcutis Biotherapeutics(ARQT.US)评级，由优于大市调整至优于大市评级, 目标价由20.00美元调整至21.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161121","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856805","title":"Arcutis Biotherapeutics, Inc.股价上涨10.20% 市值涨1.63亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856805?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580329,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Arcutis Biotherapeutics, Inc.股票出现异动，股价快速拉升10.20%。截至发稿，该股报13.45美元/股，成交量13.6755万股，换手率0.12%，振幅6.56%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2782.30%、115.75%、90.27%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为28.81%、16.85%、14.35%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223209a254f693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223209a254f693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156921339","title":"异动解读 | 亿万销售创新高,Arcutis Biotherapeutics盘前大涨9.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156921339","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156921339?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:48","pubTimestamp":1740566920,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc.于今日盘前大涨9.18%,引发市场广泛关注。此前,该公司发布了2024年第四季度财报,数据显示其销售额达到7140万美元,同比大涨427.87%,远超市场普遍预期。与销售业绩一致,Arcutis第四季度每股亏损仅为0.09美元,远低于分析师预期的0.24美元亏损。出色的业绩数据令投资者对公司未来发展充满信心,推动盘前股价大幅飙升。作为一家专注皮肤疾病创新治疗的生物科技公司,Arcutis近期的表现无疑为其在行业内赢得一席之地,并吸引更多投资者关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0411},{"period":"3month","weight":0.1998},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.8586},{"period":"ytd","weight":-0.0406}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arcutis Biotherapeutics, Inc.前身是根据特拉华州法律于2016年6月成立的，名称为Arcutis，Inc.，后将名称更改为Arcutis Biotherapeutics，Inc.。该公司是一家后期生物制药公司，致力于针对医疗需求未得到满足的皮肤病开发和商业化治疗。该公司目前的产品组合包括局部治疗，具有潜在的潜力，可以解决免疫介导的皮肤病和疾病或免疫皮肤病。该公司的策略是针对皮肤病学中经过验证的生物学目标识别和开发治疗方法，以提供差异化的临床特征，从而解决现有疗法在目标适应症方面的主要缺点。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.076618},{"month":2,"riseRate":0.857143,"avgChangeRate":0.210567},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.041444},{"month":4,"riseRate":0.428571,"avgChangeRate":0.034314},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.100595},{"month":6,"riseRate":0.857143,"avgChangeRate":0.090855},{"month":7,"riseRate":0.714286,"avgChangeRate":0.029479},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019179},{"month":9,"riseRate":0.5,"avgChangeRate":-0.050429},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.153349},{"month":11,"riseRate":0.5,"avgChangeRate":0.146122},{"month":12,"riseRate":0.666667,"avgChangeRate":0.153171}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arcutis Biotherapeutics Inc.(ARQT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arcutis Biotherapeutics Inc.(ARQT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}